Hozelock

EXEL Industries: Acquisition of French family group Devaux

Retrieved on: 
星期四, 六月 8, 2023
Hozelock, Flower, Snow, Supermarket, Sale, Wood, Gardening, Acquisition, Soil, Leisure, Growth, Environment, Family, EXEL, Management, Duchesnay, Devaux

EXEL Industries today announces the acquisition of an 81% majority stake in Devaux, a French family-owned group specializing in the manufacture and sale of gardening tools.

Key Points: 
  • EXEL Industries today announces the acquisition of an 81% majority stake in Devaux, a French family-owned group specializing in the manufacture and sale of gardening tools.
  • The Devaux Group was formed in 1992 following the takeover of Duchesnay, a manufacturer of graden tools founded in 1923, by Établissements Devaux, a company trading in garden tools founded in 1964.
  • We are proud to join a family-owned group with which we share core values: operational excellence, service culture, respect for the environment and a passion for French industrial know-how.”
    The Devaux group will become a subsidiary of Hozelock EXEL and will operate alongside the other brands of the EXEL Industries Group Garden business: Hozelock, G.F., Berthoud and Tricoflex.
  • Jean-Luc Devaux, currently Devaux group Chairman of the Board, will be Chief Executive Officer of the new entity.

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter Financial Results and Operational Highlights

Retrieved on: 
星期四, 五月 11, 2023
Federal Food, Drug, and Cosmetic Act, De novo, University, Accreditation, Initiate, Marketing, Law enforcement, Food, NATA, Research, Biosensor, Government, U.S. FDA, Organization, TTR, Acquisition, Patent, United Kingdom, FDA, Intelligence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Saliva, Pharmaceutical industry, Cryptocurrency, Television, Medical device, Drug, Video game, Hozelock

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • - Filed 513(g) submission with U.S. FDA for Intelligent Fingerprinting Drug Screening Cartridge -
    - Completion of Milestone 7, key phase of biosensor platform development -
    NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.
  • “INBS delivered revenue growth during the third quarter and achieved several important milestones in line with our regional expansion plans,” said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.
  • The results showed a record 4x improvement in time-to-result (TTR), enabling the biosensor to return test results in under one minute.
  • Third Quarter Ended March 31, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights

Retrieved on: 
星期二, 二月 14, 2023
Methamphetamine, Blood, United Kingdom, Food industry, Diagnosis, Intelligence, Research and development, Saliva, Government, OTFT, Patient, Cannabis, TTR, University, United, FDA, Growth, Calendar, Hozelock, Glucose, Biosensor, Cocaine, Cryptocurrency, Medical imaging, Medical device, Research

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced its financial results for its fiscal second quarter ended December 31, 2022, and provided a business update. All amounts are expressed in U.S. dollars unless indicated otherwise, and all authorized, issued, and outstanding stock and per share amounts reflect the 1-for-20 reverse stock split effected by the Company on February 9, 2023, unless indicated otherwise.

Key Points: 
  • “Our strong fiscal second quarter results show the expansion and strength of our global portfolio, which now includes operations in the United Kingdom, United States and Australia,” commented Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.
  • “We continued to bolster Intelligent Bio Solution’s leadership position in the field of non-invasive real-time diagnostic testing in the second quarter, achieving several significant strategic goals.
  • The results showed a record 4x improvement in TTR, enabling the biosensor to return test results in under one minute.
  • Second Quarter Ended December 31, 2022, Financial Results
    As of December 31, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $2.9 million.

Intelligent Bio Solutions Inc. Announces Global Garden Equipment Manufacturer to Introduce Intelligent Fingerprinting Drug Tests

Retrieved on: 
星期二, 一月 31, 2023
Policy, Privacy, Health, Intelligence, Safety, Cannabis, Urine, Cocaine, Methamphetamine, Perspiration, Medical device, Pharmaceutical industry, Hozelock, Unite

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), today announced that global garden equipment manufacturer Hozelock will implement drug tests utilizing fingerprint sweat-based technology from the Company’s subsidiary, Intelligent Fingerprinting , to promote employee safety.

Key Points: 
  • NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), today announced that global garden equipment manufacturer Hozelock will implement drug tests utilizing fingerprint sweat-based technology from the Company’s subsidiary, Intelligent Fingerprinting , to promote employee safety.
  • Hozelock will use the fingerprint sweat-based drug test to determine any recent employee use of cocaine, cannabis, methamphetamine or opioids.
  • The Intelligent Fingerprinting platform, which analyzes sweat to screen for recent drug use, is quick, hygienic and non-invasive, and enables Hozelock’s Human Resources (HR) staff members to easily conduct drug tests whenever necessary.
  • As the Intelligent Fingerprinting system is portable and visual, the operation of on-site drug tests also provides a great way of promoting Hozelock’s drug use policy to new employees and potential employees.

EXEL Industries: 2021-2022 ful-year results

Retrieved on: 
星期二, 十二月 20, 2022
Commercial, NFD, SIMA, Growth, Robotics, Laurent Wauquiez, Exhibition, Policy, Attention, CSR, Statutory auditor, Silent Scope 3, Gardening, Farmer, Marketing, Annual, Agriculture, Renewable energy, Bank, Holding company, Milk, EBITDA, Hozelock

In response to rising raw material and component costs, EXEL Industries has endeavored to optimally adjust prices across all business lines.

Key Points: 
  • In response to rising raw material and component costs, EXEL Industries has endeavored to optimally adjust prices across all business lines.
  • Furthermore, the EXEL Industries Group has lines of credit that allow it to support its operating and, where applicable, external growth requirements.
  • In 2021–2022, EXEL Industries launched a new initiative at Group level to identify the main catalysts to reduce its Scope 3 greenhouse gas emissions.
  • Lastly, EXEL Industries has assigned greater priority to sustainable development in its strategy.”

EXEL INDUSTRIES :2020-2021 Full-year results : Significant improvement in margins combined with a sharp reduction in debt

Retrieved on: 
星期五, 十二月 17, 2021
EBITDA, Board of directors, Pressure, Element, Net, Agricultural spray adjuvant, Board, Euronext Paris, Growth, CSR, Group, Income, Acquisition, Laurent Wauquiez, SRD, Capital, Intec, CEO, EXEL, Achievement, Â, Efficiency, Hozelock, Statutory auditor, Annual, Mission statement, Animal, Bank

This favorable impact was offset by negative foreign exchange rate effects linked notably to the US dollar (down 11.6 million).

Key Points: 
  • This favorable impact was offset by negative foreign exchange rate effects linked notably to the US dollar (down 11.6 million).
  • Production costs were subject to strong and continuous inflation over the year, including raw materials, components and logistics.
  • Furthermore, the EXEL Industries group has lines of financing that allow it to support its operating and, where applicable, external growth requirements.
  • EXEL Industries employs approximately 3,546 permanent employees spread across 27 countries and five continents.